Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.35 |
| ▸ | FEN1 | P39748 | 7/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 6/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489421 | 0.84 | THRB (0.38) | CA2CHKAALOX5APFEN1ELOVL1 | |
| SCHEMBL16291043 | 0.80 | MAPT (0.38) | CA2CHKAALOX5APFEN1ELOVL1 | |
| SCHEMBL11373823 | 0.78 | PIK3CD (0.37) | CA2CHKAALOX5APFEN1ELOVL1 | |
| SCHEMBL20172295 | 0.77 | TSHR (0.41) | — | |
| SCHEMBL15933168 | 0.76 | HDAC1 (0.36) | ELOVL1 | |
| SCHEMBL16608094 | 0.76 | RXRA (0.38) | ELOVL1APPBRAFKDRMAPK14 | |
| SCHEMBL10187279 | 0.76 | MCHR1 (0.41) | CA2CHKAALOX5APFEN1ELOVL1 | |
| SCHEMBL2237291 | 0.76 | HTR7 (0.46) | ELOVL1MAPT | |
| SCHEMBL10188104 | 0.75 | ALDH1A1 (0.39) | CA2CHKAALOX5APFEN1ASIC3 | |
| SCHEMBL28200612 | 0.75 | CA2 (0.38) | CA2CHKAALOX5APFEN1ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CA2 3052/4885CHKA 71/4885ALOX5AP 3927/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CA2 3052/4885CHKA 71/4885ALOX5AP 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.